DK0700299T3 - Oxygen-reduceret, vandig faktor VIII-opløsning - Google Patents

Oxygen-reduceret, vandig faktor VIII-opløsning

Info

Publication number
DK0700299T3
DK0700299T3 DK94915307T DK94915307T DK0700299T3 DK 0700299 T3 DK0700299 T3 DK 0700299T3 DK 94915307 T DK94915307 T DK 94915307T DK 94915307 T DK94915307 T DK 94915307T DK 0700299 T3 DK0700299 T3 DK 0700299T3
Authority
DK
Denmark
Prior art keywords
factor viii
pct
oxygen
aqueous solution
solution
Prior art date
Application number
DK94915307T
Other languages
English (en)
Inventor
Thomas Oesterberg
Angelica Fatouros
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Application granted granted Critical
Publication of DK0700299T3 publication Critical patent/DK0700299T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK94915307T 1993-05-07 1994-03-24 Oxygen-reduceret, vandig faktor VIII-opløsning DK0700299T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE19939301581A SE9301581D0 (sv) 1993-05-07 1993-05-07 Protein formulation
PCT/SE1994/000265 WO1994026286A1 (en) 1993-05-07 1994-03-24 Oxygen-reduced aqueous solution of factor viii

Publications (1)

Publication Number Publication Date
DK0700299T3 true DK0700299T3 (da) 2002-09-23

Family

ID=20389868

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94915307T DK0700299T3 (da) 1993-05-07 1994-03-24 Oxygen-reduceret, vandig faktor VIII-opløsning

Country Status (24)

Country Link
US (1) US5962650A (da)
EP (1) EP0700299B1 (da)
JP (1) JP3751633B2 (da)
KR (1) KR100304143B1 (da)
CN (1) CN1113655C (da)
AT (1) ATE218354T1 (da)
AU (1) AU681883B2 (da)
CA (1) CA2161350C (da)
CZ (1) CZ293527B6 (da)
DE (1) DE69430745T2 (da)
DK (1) DK0700299T3 (da)
EE (1) EE03118B1 (da)
ES (1) ES2177579T3 (da)
FI (1) FI111910B (da)
HU (1) HU215263B (da)
NO (1) NO321769B1 (da)
NZ (1) NZ266031A (da)
PL (1) PL174866B1 (da)
PT (1) PT700299E (da)
RU (1) RU2142290C1 (da)
SE (1) SE9301581D0 (da)
SK (1) SK283002B6 (da)
WO (1) WO1994026286A1 (da)
ZA (1) ZA942251B (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5929031A (en) * 1995-05-02 1999-07-27 Baxter Biotech Technology Sarl Storage stable hemoglobin solutions
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
CZ300547B6 (cs) 1999-02-22 2009-06-10 University Of Connecticut Nové formulace faktoru VIII prosté albuminu
DE60024268T2 (de) * 1999-07-13 2006-08-03 Biovitrum Ab Zusammensetzungen mit stabilem faktor viii
JP3466516B2 (ja) 1999-09-07 2003-11-10 科学技術振興事業団 安定保存可能な酸素輸液剤
RU2004122430A (ru) * 2001-12-21 2005-04-20 Ново Нордиск А/С (DK) Жидкая композиция полипептидов модифицированного фактора vii
ATE428439T1 (de) * 2001-12-21 2009-05-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzung aus faktor vii polypeptiden
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
EP2283856B1 (en) * 2002-06-21 2017-09-20 Novo Nordisk Health Care AG Stabilised solid compositions of factor VIIa polypeptides
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
RU2364609C2 (ru) 2003-05-23 2009-08-20 Ново Нордиск Хелт Кэр Аг Стабилизация белка в растворе
ES2382157T3 (es) * 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
DE602004023848D1 (de) * 2003-07-01 2009-12-10 Novo Nordisk Healthcare Ag Von factor vii polypeptiden
CA2534028A1 (en) 2003-08-14 2005-02-24 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
EP1703899B1 (en) 2003-12-19 2011-05-04 Novo Nordisk Health Care AG Stabilised compositions of factor vii polypeptides
EP1750733B1 (en) 2004-05-03 2013-12-11 Emory University METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII
US7494974B2 (en) 2006-10-24 2009-02-24 Ikor, Inc. Carboxymethylated cross-linked tetrameric hemoglobin
US7504377B2 (en) 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
ES2344719T3 (es) * 2007-04-17 2010-09-03 DR. WILLMAR SCHWABE GMBH & CO. KG Procedimiento para la preparacion de soluciones estables en almacenamiento de extractos de pelargonio.
ES2364118T3 (es) * 2007-07-11 2011-08-25 Novo Nordisk A/S Purificación de factor viii usando una resina de modo mixto o multimodal.
EP2113564A1 (en) 2008-05-01 2009-11-04 Arecor Limited Protein formulation
AU2009284113B2 (en) 2008-08-21 2015-05-14 Octapharma Ag Recombinantly produced human factor VIII and IX
US20110178019A1 (en) * 2008-09-03 2011-07-21 Brita Rippner New protecting compositions for recombinantly produced factor viii
WO2010054238A1 (en) 2008-11-07 2010-05-14 Baxter International Inc. Factor viii formulations
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
DK2440239T3 (da) * 2009-06-09 2017-10-16 Prolong Pharmaceuticals Llc Hæmoglobinsammensætninger
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US9199016B2 (en) 2009-10-12 2015-12-01 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
EP2608816B1 (en) 2010-08-25 2023-07-05 Hemanext Inc. Method for enhancing red blood cell quality and survival during storage
AU2011323236B2 (en) 2010-11-05 2017-03-30 Takeda Pharmaceutical Company Limited A new variant of antihemophilic factor VIII having increased specific activity
EP2635114B1 (en) 2010-11-05 2020-04-29 New Health Sciences, Inc. Irradiation of red blood cells and anaerobic storage
US9067004B2 (en) 2011-03-28 2015-06-30 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
CA2844449A1 (en) 2011-08-10 2013-02-14 New Health Sciences, Inc. Integrated leukocyte, oxygen and/or co2 depletion, and plasma separation filter device
CA3205441A1 (en) 2013-02-28 2014-09-04 Hemanext Inc. Gas depletion and gas addition devices for blood treatment
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
BR112017019279B1 (pt) 2015-03-10 2022-02-08 Hemanext Inc Dispositivos de depleção de oxigênio e armazenamento de sangue e método para preparar sangue para armazenamento, método para reduzir o oxigênio a partir do sangue total e método de preparação de um recipiente de sangue flexível interno
BR122022005103B1 (pt) 2015-04-23 2023-03-14 Hemanext Inc Dispositivo de armazenamento de sangue para armazenar sangue depletado de oxigênio e método para armazenar sangue depletado de oxigênio
BR122021024410B1 (pt) 2015-05-18 2022-05-03 Hemanext Inc Métodos para gerenciar um banco de sangue e para prover fornecimento de produtos de sangue total armazenados para medicina de transfusão
ES2910948T3 (es) 2016-05-27 2022-05-17 Hemanext Inc Almacenamiento anaeróbico de sangre y procedimiento de inactivación de patógenos
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2896381A (en) * 1954-05-27 1959-07-28 Hodes Lange Corp Method and apparatus for treating and filling ampoules
US3143471A (en) * 1962-01-18 1964-08-04 Merck & Co Inc Argon method of drying and preserving lyophilized therapeutic products
US4165370A (en) * 1976-05-21 1979-08-21 Coval M L Injectable gamma globulin
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3144705C2 (de) * 1981-11-11 1983-12-08 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4727027A (en) * 1983-05-02 1988-02-23 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
DE3577801D1 (de) * 1985-08-05 1990-06-28 Immuno Ag Verfahren zur herstellung von praeparationen auf basis von blutgerinnungsfaktoren.
US4709819A (en) * 1986-07-23 1987-12-01 Environmental Diagnostics, Inc. Method for preserving plated media and product
CA1292686C (en) * 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
GB8808810D0 (en) * 1988-04-14 1988-05-18 Biopharm Clinical Research Ltd Heparin-containing formulations
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
BR9509132A (pt) * 1994-10-31 1997-09-02 Kimberly Clark Co Aparelho para tratamento intraluminal processo para tratamento e irradisção de área selecionada e processo para tratamento de local de bloqueio arterosclerótico

Also Published As

Publication number Publication date
CA2161350C (en) 2007-10-30
FI955305A0 (fi) 1995-11-06
HU9503171D0 (en) 1996-01-29
PT700299E (pt) 2002-11-29
NO954457D0 (no) 1995-11-07
NO321769B1 (no) 2006-07-03
FI111910B (fi) 2003-10-15
NZ266031A (en) 1997-04-24
US5962650A (en) 1999-10-05
DE69430745T2 (de) 2002-10-17
EP0700299A1 (en) 1996-03-13
AU681883B2 (en) 1997-09-11
CZ286995A3 (en) 1996-05-15
JP3751633B2 (ja) 2006-03-01
PL174866B1 (pl) 1998-09-30
FI955305A (fi) 1995-11-06
SK138395A3 (en) 1997-02-05
CA2161350A1 (en) 1994-11-24
RU2142290C1 (ru) 1999-12-10
KR100304143B1 (ko) 2001-11-22
HU215263B (hu) 1998-11-30
DE69430745D1 (de) 2002-07-11
CN1122573A (zh) 1996-05-15
AU6659794A (en) 1994-12-12
JPH08509745A (ja) 1996-10-15
PL311567A1 (en) 1996-02-19
HUT73693A (en) 1996-09-30
CZ293527B6 (cs) 2004-05-12
KR960702317A (ko) 1996-04-27
CN1113655C (zh) 2003-07-09
ES2177579T3 (es) 2002-12-16
EE03118B1 (et) 1998-10-15
SK283002B6 (sk) 2003-01-09
SE9301581D0 (sv) 1993-05-07
ZA942251B (en) 1994-11-01
EP0700299B1 (en) 2002-06-05
ATE218354T1 (de) 2002-06-15
WO1994026286A1 (en) 1994-11-24
NO954457L (no) 1995-11-07

Similar Documents

Publication Publication Date Title
DK0700299T3 (da) Oxygen-reduceret, vandig faktor VIII-opløsning
BR9607922A (pt) Produto medicamentoso final de uma proteína de plasma processos para preparar o produto medicamentoso final para melhorar a estabilidade de longo prazo de uma proteína de plasma e para tratar hemofilia e uso de um produto medicamentoso final
ATE73671T1 (de) Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin.
PL320342A1 (en) Thrombin inhibitor containing infusion solution, stable during storage
SE9402119D0 (sv) Solution
ATE66147T1 (de) Verwendung von pteridinen und/oder purinen oder eines xanthinoxidase-hemmers zur herstellung eines arzneimittels zur behandlung von genetisch bedingten degenerativen netzhauterkrankungen.
GR3036277T3 (en) Methods for preventing degradation of protein C.
TH19245A (th) วิธีป้องกันการสลายของโปรตีนซี